As of early January 2026, China's biopharmaceutical sector is preparing for a historic year, with projections of approximately 94 innovative drug approvals—many accelerated through priority review to address critical unmet needs in rare diseases, oncology, and chronic infections. These advancements signal a clear evolution: from rapid domestic growth to high-value innovations increasingly aligned with global standards, ready for international collaboration and broader patient access.

At Hong Kong DengYue Medicine (dengyuemed.com), we have always held that the deepest impact in healthcare arises from an unwavering commitment to excellence, innovation, sustainability, and social responsibility. By placing quality, regulatory compliance, and integrity at the core of everything we do, we actively engage in the global pharmaceutical landscape—not only supporting China's homegrown innovations as they expand overseas, but also contributing meaningfully to health and well-being worldwide.

Four standout candidates from the 2026 priority-review pipeline vividly illustrate this progress:

• Lebetamab (立贝韦塔单抗) – Huahui Anjian Indication: Chronic hepatitis D Highlights: First-in-class monoclonal antibody that blocks viral entry; phase IIb trials showed robust viral suppression, liver enzyme normalization, and reduced liver stiffness with excellent long-term tolerability. Granted breakthrough therapy designation in China and recognized by the FDA—positioning it to fill a major gap for patients in endemic regions across Asia, Africa, and Europe.
• Ruixiqibai (瑞西奇拜单抗) – Huahai Pharma Indication: Generalized pustular psoriasis (GPP) Highlights: China's first domestically developed IL-36R inhibitor; pivotal studies demonstrated rapid and significant pustule clearance after just one dose, with a strong safety profile. Delivers the kind of swift, transformative relief that patients with this unpredictable and debilitating condition have long needed.
• Anruitini (安瑞替尼) – Weikaier Pharma Indication: NTRK fusion-positive solid tumors Highlights: Next-generation TRK inhibitor designed to overcome resistance mutations; encouraging clinical activity seen in treatment-naïve, previously treated, and brain-metastatic cases. Strengthens precision oncology options for rare but aggressive fusion-driven cancers.
• Tengotini (替恩戈替尼) – Yaojie Ankang Indication: Advanced cholangiocarcinoma (particularly FGFR-altered) Highlights: Multi-kinase inhibitor targeting both tumor cells and their microenvironment; delivered progression-free survival beyond six months and overall survival of 15–17+ months in later-line patients. Provides valuable new possibilities for a cancer with historically limited treatment outcomes.

These therapies represent far more than clinical milestones—they embody China's maturing R&D capabilities in biologics, rare diseases, and precision medicine, while paving the way for meaningful global contributions. For patients and families facing these challenging diagnoses, 2026 offers realistic grounds for optimism: innovative, high-quality treatments originating in China are steadily advancing toward transforming care at home and around the world.